HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:

Title: Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment
Authors: Hosoda, Shunichi Browse this author
Suda, Goki Browse this author →KAKEN DB
Sho, Takuya Browse this author
Ogawa, Koji Browse this author
Kimura, Megumi Browse this author
Yang, Zijian Browse this author
Yoshida, Sonoe Browse this author
Kubo, Akinori Browse this author
Tokuchi, Yoshimasa Browse this author
Kitagataya, Takashi Browse this author
Maehara, Osamu Browse this author
Ohnishi, Shunsuke Browse this author
Nakamura, Akihisa Browse this author
Yamada, Ren Browse this author
Ohara, Masatsugu Browse this author
Kawagishi, Naoki Browse this author
Natsuizaka, Mitsuteru Browse this author
Nakai, Masato Browse this author
Morikawa, Kenichi Browse this author
Furuya, Ken Browse this author
Baba, Masaru Browse this author
Yamamoto, Yoshiya Browse this author
Suzuki, Kazuharu Browse this author
Izumi, Takaaki Browse this author
Meguro, Takashi Browse this author
Terashita, Katsumi Browse this author
Ito, Jun Browse this author
Miyagishima, Takuto Browse this author
Sakamoto, Naoya Browse this author →KAKEN DB
Keywords: Atezolizumab
Early PD
Hepatocellular carcinoma
Issue Date: Jun-2023
Publisher: Karger
Journal Title: Liver Cancer
Volume: 12
Issue: 2
Start Page: 156
End Page: 170
Publisher DOI: 10.1159/000527759
Abstract: Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial.Methods: Patients with unresectable HCC treated with atezolizumab plus bevacizumab and had baseline preserved serum (n = 68) were screened and classified according to their PD, six weeks after treatment initiation (early PD; n = 13). Of these, four patients each with and without early PD were selected for cytokine array and genetic analyses. The identified factors were validated in the validated cohort (n = 60) and evaluated in patients treated with lenvatinib.Results: No significant differences were observed in the genetic alterations in circulating tumor DNA. Cytokine array data revealed that baseline MIG (CXCL9), ENA-78, and RANTES differed substantially between patients with and without early PD. Subsequent analysis in the validation cohort revealed that baseline CXCL9 was significantly lower in patients with early PD than that in patients without early PD, and the best cut-off value of serum CXCL9 to predict early PD was 333 pg/mL (sensitivity: 0.600, specificity: 0.923, AUC = 0.75). In patients with lower serum CXCL9 (< 333 pg/mL), 35.3% (12/34) experienced early PD with atezolizumab plus bevacizumab, while progression-free survival (PFS) was significantly shorter relative to that in patients without (median PFS, 126 days vs 227 days; HR: 2.41, 95% CI: 1.22-4.80, p = 0.0084). While patients with objective response to lenvatinib had significantly lower CXCL9 levels compared with those of patients without.Conclusion: Baseline low serum CXCL9 (< 333 pg/mL) levels may predict early PD in patients with unresectable HCC treated with atezolizumab plus bevacizumab.
Type: article
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 - Hokkaido University